Analyst Reco. BeOne Medicines AG

Stocks

ONC

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
264.48 ^USD	+1.62%		-2.08%	-12.95%

12/06	BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses	MT
12/06	Beone Medicines AG Approves Board and Committee Elections	CI

Analyst Reco.

02/06	RBC Raises Price Target on BeOne Medicines to $436 From $425, Keeps Outperform Rating	MT
07/05	RBC Capital Adjusts BeOne Medicines PT to $425 From $423, Maintains Outperform Rating	MT
04/05	Wells Fargo Initiates Coverage on BeOne Medicines AG With Overweight Rating	MT
07/04	RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating	MT
27/02	RBC Lifts Price Target on BeOne Medicines to $425 From $417, Keeps Outperform Rating	MT
13/02	Nomura Adjusts BeOne Medicines Price Target to $442.91 From $366.06, Maintains Buy Rating	MT
13/02	Nomura Adjusts BeOne Medicines' Price Target to HK$263.69 From HK$217.94, Keeps at Buy	MT
08/01	RBC Raises Price Target on BeOne Medicines to $417 From $408, Keeps Outperform Rating	MT
10/12	BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says	MT
18/11	RBC Raises Price Target on BeOne Medicines to $408 From $395, Keeps Outperform Rating	MT
07/11	RBC Capital Adjusts Price Target on BeOne Medicines to $395 From $374, Maintains Outperform Rating	MT
20/25/20	BeOne Medicines Ltd. Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025	CI
13/25/13	BeOne Says Lymphoma Therapy Granted FDA Breakthrough Designation	MT
13/25/13	BeOne Medicines' sonrotoclax granted breakthrough therapy designation by U.S. FDA	RE
08/25/08	RBC Lifts Price Target on BeOne Medicines to $374 From $364, Keeps Outperform Rating	MT
07/25/07	RBC Raises Price Target on BeOne Medicines to $364 From $349, Keeps Outperform Rating	MT
07/25/07	Nomura Adjusts BeOne Medicines Price Target to $366.06 From $352.60, Maintains Buy Rating	MT
07/25/07	Nomura Adjusts BeOne Medicines' Price Target to HK$217.94 From HK$209.92, Keeps at Buy	MT
18/25/18	Nomura Adjusts BeOne Medicines Price Target to $352.60 From $347.02, Maintains Buy Rating	MT
18/25/18	Nomura Adjusts BeOne Medicines' Price Target to HK$209.92 From HK$206.60, Keeps at Buy	MT
16/25/16	RBC Raises Price Target on BeOne Medicines to $349 From $311, Keeps Outperform Rating	MT
08/25/08	RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating	MT
07/25/07	RBC Initiates BeiGene at Outperform With $312 Price Target	MT
03/25/03	BofA Securities Upgrades BeiGene to Buy, Price Target is $320	MT
03/25/03	Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating	MT